While the allogeneic vs autologous debate continues in the cell therapy field, research on in vivo therapies is drawing ...

CARGO Therapeutics (CRGX, Financials) saw its stock jump 18.9% pre-market to $4.52 on Wednesday after announcing it would ...

Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize ...

Just a few months after dumping its lead asset and cutting its workforce in half, Cargo Therapeutics is jettisoning even more ...

Advancements in newer therapies are expected to drive its expansion. A rise in incident cases, expanded use of existing ...

CARGO Therapeutics (NASDAQ:CRGX) shares rose after market hours as the company announced a 90% workforce reduction along with ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

In this interview, News Medical speaks with Olivier Negre, Chief Scientific Officer at Smart Immune, about how immunotherapy is being revolutionized.

In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...

This partnership spans allogeneic cell therapies currently in preclinical development for cancer. AstraZeneca also has the opportunity to improve on the manufacturability of autologous cell therapy.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...